International Research Journal of Medicine and Biomedical Sciences

Hepatitis B reactivation with hepatic decompensation after the use of direct-acting antiviral agents in a patient with chronic Hepatitis B and C coinfection

Po-Yao Hsu

Ming-Lun Yeh

Chung-Feng Huang

Chia-Yen Dai

Ming-Lung Yu

Jee-Fu Huang

Wan-Long Chuang

Article Number: irjmbs.19.007  |   Pages: 38-41  |   Vol.4 (4), October, 2019   |   DOI:

 Received: August 12, 2019  Accepted: October 5, 2019  Published: October 24, 2019


In recent years, direct-acting antiviral agents (DAAs) have become the major therapy for Hepatitis C virus (HCV) infection and chronic Hepatitis C (CHC). However, Hepatitis B virus (HBV) reactivation (HBVr) remains an important issue among patients with HBV/HCV coinfection when receiving DAAs for CHC. The severity of HBVr-induced Hepatitis may range from a mild to a severe form of liver injury. In this study, we present a rare case of HBVr leading to a decompensated state and jaundice in a 72-year-old man during DAA treatment. His decompensated state subsequent to HBVr, fortunately improved after initiating oral antiviral treatment for HBV. Our case highlights the importance of the pretreatment evaluation of patients for HBV, monitoring potential HBVr, and the initiation of HBV antiviral therapy in HBV/HCV coinfected patients.


Direct-acting antiviral agents, chronic Hepatitis C, Hepatitis B virus reactivation, decompensation

How to Cite this Article

Author(s) retain the copyright of this article. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.